news
NICE recommends Novartis’ heart failure drug, Entresto
21 March 2016 | By Victoria White
The UK’s National Institute for Health and Care Excellence (NICE) has recommended Novartis’ heart failure drug, Entresto (sacubitrial/valsartan).
List view / Grid view
Novartis
news
Cosentyx superior to Stelara in achieving sustained skin clearance in psoriasis
New late-breaking data from Novartis’ head-to-head CLEAR study demonstrates that Cosentyx (secukinumab) remains superior to Stelara (ustekinumab) in achieving sustained skin clearance (PASI 90 response) at 52 weeks for adults living with moderate-to-severe psoriasis.
news
FDA grants Breakthrough Therapy status to PKC412 (midostaurin)
19 February 2016 | By Victoria White
PKC412 (midostaurin) is an investigational treatment for adults with newly-diagnosed acute myeloid leukaemia who are FLT3 mutation-positive...
news
Eye care company Alcon acquires Transcend Medical
18 February 2016 | By Victoria White
This Transcend Medical acquisition also expands Alcon's leadership in glaucoma and cataract treatment...
news
Cosentyx to achieve blockbuster status
27 January 2016 | By Victoria White
Alexandra Annis states that Cosentyx's latest approval will bring exciting new treatment options to US patients dissatisfied with current therapies...
news
NICE recommends five new therapies
27 January 2016 | By Victoria White
NICE has published its final recommendations on whether six different drug treatments should be routinely funded by the NHS...
news
FDA approves Novartis’ Cosentyx for AS and PsA
18 January 2016 | By Victoria White
Cosentyx (secukinumab) is a fully human monoclonal antibody that selectively neutralizes circulating interleukin-17A (IL-17A)...
news
NICE says ‘yes’ to heart failure drug sacubitril valsartan
11 December 2015 | By Victoria White
Sacubitril valsartan is an angiotensin receptor neprilysin inhibitor. Neprilysin inhibits the actions of peptides in dilating the blood vessels...
news
CTL019 demonstrates 93% remission in paediatric patients with r/r ALL
8 December 2015 | By Victoria White
This finding comes from from an ongoing Phase II study of CTL019 and, Novartis says, further support its potential in the treatment of paediatric patients with relapsed/refractory acute lymphoblastic leukaemia...
news
EC grants marketing authorisation to Entresto
25 November 2015 | By Victoria White
The European Commission has granted marketing authorisation to Novartis’ Entresto (sacubitril/valsartan) for the treatment of adult patients with symptomatic chronic heart failure with reduced ejection fraction (HFrEF).
news
Novartis’ secukinumab gains two landmark EU approvals
23 November 2015 | By Victoria White
The EC has approved secukinumab (Costenyx) for the treatment of people living with ankylosing spondylitis and psoriatic arthritis...
news
Novartis announces new trial results for Ultibro Breezhaler in COPD
17 November 2015 | By Victoria White
Once-daily Ultibro Breezhaler met its primary endpoint (non-inferiority) and also demonstrated superiority to twice-daily Seretide...
news
Dr Vasant Narasimhan elected a member of the US National Academy of Medicine
11 November 2015 | By Victoria White
The US National Academy of Medicine (NAM) recently announced the election of Dr Vasant “Vas” Narasimhan as a member of the Academy.
news
CHMP recommends approval of Cosentyx for ankylosing spondylitis and psoriatic arthritis
23 October 2015 | By Victoria White
Cosentyx Phase III studies have consistently demonstrated significant improvements in the signs and symptoms of ankylosing spondylitis and psoriatic arthritis...
news
Novartis expands its cancer immunotherapy portfolio
21 October 2015 | By Victoria White
Novartis is broadening its portfolio of cancer immunotherapies through the acquisition of Admune Therapeutics and licensing agreements with Palobiofarma and XOMA Corporation...
